U.S. Court Says Roche’s Cera Anemia Treatment Infringes on One Amgen Patent

With a U.S. federal district court ruling on Tuesday that Swiss drug maker Roche Holding AG’s anemia drug pegylated EPO product infringes on Amgen’s EPO pharmaceutical composition patent, biotechnology giant Amgen Inc. appears one step closer to cementing its hegemony in the erythropoietin or EPO market.
RTTNews